Results 251 to 260 of about 75,785 (301)

Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T. [PDF]

J Immunother Cancer
Wang N, Liu L, Zhang L, Li J, Wan Y, Li X, Chen X, Yin Z, Zhang A, Zhang X, Chen Y, Hu T, Zhang Y, Liu F, Zhu X, Yang W.   +15 more
europepmc   +1 more source

Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy. [PDF]

Kidney Int Rep
Cheddadi Y, El Maï M, Brglez V, Nahon Carzo S, Cremoni M, Teisseyre M, Seitz-Polski B.   +6 more
europepmc   +1 more source

Development of antigen multimers for detection and evaluation of CAR T cells. [PDF]

Cancer Immunol Immunother
Friis RUW, Ormhøj M, Krüger-Jensen CS, Pardo CR, Halldórsdóttir HR, Barden M, Kristensen NP, Ramanathan K, Hansen MR, Abken H, Hadrup SR.   +10 more
europepmc   +1 more source

Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges. [PDF]

Biomedicines
Rotte A, Sopjani M, Bhandaru M.
europepmc   +1 more source

CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. [PDF]

Front Immunol
Li J, Guo Q, Li L, Wang J, Zhang L.
europepmc   +1 more source

Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives. [PDF]

Front Pediatr
Ling W, Xu C, Tang J, Lu S, Wu C.
europepmc   +1 more source

The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies.

Biochim Biophys Acta Rev Cancer
Krawczyk M, Drużyńska M, Bednarska E, Winiarska M.   +3 more
europepmc   +1 more source